As many as 1 in 3 urine cultures come back negative, yet the burning and urgency keep coming. A Cornell Tech spinout says the infection is often still there: in a study of 200+ culture-negative samples, its sequencing test found a pathogen in 63% of them. Biotia just raised $9M to take that approach into places where a wrong guess costs even more, including a type of infection that surgeons dread. Find out why the company thinks the next big diagnostic gap sits inside the joint.